PROKIDNEY CORP. - 8-K Filing
ProKidney Corp. reports Q3 2026 results with $141.9 million in liquidity and increased R&D spending driven by Phase 3 PROACT 1 study. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PROK
Read the full article at SEC EDGAR
Part of the story Horizon Kinetics Holding Corp - 8-K Filing (3 articles)